Home     Site Map     Legal   

  Scientific Advisory Board

  • L. Michael Glodè, M.D. - SAB Chairman
Dr. Glodè is Professor Emeritus at the Colorado University Cancer Center and former Robert Rifkin Professor for prostate cancer research. He has focused his clinical career on prostate cancer and GU malignancies. He was the founding editor of ASCO OnLine, the official website of the American Society of Clinical Oncology and has also been recognized by the American Association of Cancer Research for initiation of a molecular biology course for clinical oncologists held each year in Aspen. He has authored more than 150 articles and book chapters. He is currently President of Aurora Oncology and active serial entrepreneur who has had multiple SBIR/STTR competitive grants.
  • Nebojsa Janjic, Ph.D.
Dr. Janjic is the Chief Scientific Officer at SomaLogic, Inc. Prior to joining SomaLogic, Dr. Janjic was the CSO at Replidyne, Inc. in Louisville, Colorado, a biotechnology company focusing on the development of new small-molecule antibacterial agents.Prior to joining Replidyne, Dr. Janjic was Senior Director, Drug Discovery, at NeXstar Pharmaceuticals in Boulder, Colorado. Dr. Janjic joined NeXstar in its formative stages and participated in its development to a publicly-traded biotechnology company valued in excess of $500 million. At NeXstar, Dr. Janjic was responsible for creating a pipeline of aptamer-based drug candidates for pre-clinical and clinical development. His contributions included the discovery and early development of Macugen, the first-in-class FDA-approved treatment for macular degeneration and named Innovative Pharmaceutical Product of the Year in 2005. Dr. Janjic's duties also included technology transfer to major corporate partners and linking of discovery research efforts with business development activities. Dr. Janjic is an author of 30 original research papers and an inventor on 10 issued patents. Dr. Janjic received his B.S. degree in Molecular Biology and Ph.D. in Physical Organic Chemistry from the University of Washington in Seattle and completed his postdoctoral training at the Scripps Research Institute in La Jolla as a Cancer Research Institute Fellow. 
  • Michael T. McDermott, M.D.
Dr. McDermott joined the University of Colorado Endocrinology Division in 1997 as Director of the Clinical Endocrinology Practice.  Prior to this prestigious appointment, he spent 20 years in the U.S. Army serving as a general endocrinologist and later as the Chief of the Endocrine Service and Endocrine Fellowship program at Fitzsimons Army Medical Center and as the Endocrine consultant to the Surgeon General.  His clinical research interests include the pathophysiology and treatment of osteoporosis and related metabolic diseases and the pathophysiology of diseases of the thyroid gland. His basic research interests involved studying the molecular events underlying the development of thyroid and pituitary tumors.
  • Douglas H.Thamm V.M.D., DACVIM (oncology)
Dr. Thamm is the Barbara Cox Anothony Professor of Oncology and Director of Clinical Research at the Flint Animal Cancer Center at Colorado State University. He is the author of over 150 peer-reviewed publications, 20 book chapters and 175 research abstracts in the field of veterinary oncology and cancer research. His clinical interests include novel targeted, cytotoxic and biotherapies for animal cancer and the translational application of these therapies to human oncology. .



MBC Pharma, Inc.   12635 E. Montview Blvd., Suite 100  Aurora, CO 80045
Phone: 720-859-4041  Fax: 303-484-3532
Email: information@mbcpharma.com